Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Amniotics Receives Approval for Phase I/II Study of Pulmostem™ in Hospitalized COVID-19 Patients
Amniotics AB (publ) (Nasdaq Stockholm: AMNI) today announced that it has received approval by regulatory […]
Amniotics Strengthens its Clinical and Regulatory Capabilities
Amniotics AB (publ) (Nasdaq Stockholm: AMNI), a developer of novel cell therapy products, has appointed […]
Amniotics Secures Funding of SEK 4,8 Million from Vinnova to Develop Stem Cell Therapies
Amniotics AB (publ) (Nasdaq Stockholm: AMNI) today announced that it has received a non-diluting grant […]
Amniotics Joins Vinnova Funded ’CAMP’ to Improve Outcome of Lung Transplantations with PulmoStem™
Amniotics AB (publ) (Nasdaq Stockholm: AMNI), a developer of novel cell therapy products, today announced that […]
Stem Cell Therapy Company Amniotics Raises SEK 60 Million
Amniotics AB (publ) (“Amniotics” or the “Company”), a stem cell therapy company has raised SEK60 million through […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more